Our manager is all about Estrace. This force will slowly erode to next to nothing. Liletta will take off when it gets the 5 year indication. It will take market leadership when it gets 7. Assuming the price is still advantageous.
They are dumping Minastrin next quarter. Which makes no sense. We pick up an IBS drug and drop an actual women's health product. Go figure
Estrace is still crazy expensive The coupons sometimes work and coverage is so convoluted it makes no sense. Our Med D coverage is spotty at best. If you want to capture the Commercial business make it easier to get the discount or get better Med D coverage so those people quit calling in!